Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2012

View Archived Issues

Itraconazole shows promise as an antiangiogenic and antitumor agent

New amatoxin conjugates patented by Heidelberg Pharma

Novel LRRK2 inhibitors prepared at Merck & Co.

Orchid Chemicals & Pharmaceuticals discloses new HDAC6 inhibitors

Japanese researchers synthesize new vitamin D receptor modulators

Novel anticancer agents presented by Kitasato Institute

New OGA inhibitors patented by Summit Corporation

Companies to develop self-injectable treprostinil

NX-1207 prostate cancer trial receives positive interim safety review

MBC Pharma and Maxwell Biotech enter joint venture in metastatic bone disease

FDA approves denosumab in new indication

MorphoSys reports phase Ib/IIa MOR-103 study results

Aradigm's inhaled liposomal ciprofloxacin shows promise in mouse models

First-in-human study of Opal-HIV-Gag(c) terminated

Eliglustat efficacy maintained for 4 years in patients with Gaucher's disease

Astex Pharmaceuticals discontinues amuvatinib development

Navidea Biopharmaceuticals receives NIH grant to develop RIGS agent

EMA committee recommends approval of new apixaban indication

ViroPharma and Halozyme provide update on development of Cinryze/rHuPH20

Sequestosome-1 identified as a biomarker of melanoma

CHMP recommends Constella in IBS-C

NewLink and Dendreon to collaborate on phase II study of combination treatment for prostate cancer

VIVUS anticipates CHMP opinion on Qsiva MAA

CHMP recommends expanded approval of Trajenta tablets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...